These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 12242540

  • 21. Serum prolactin levels in Parkinson's disease and multiple system atrophy.
    Winkler AS, Landau S, Chaudhuri KR.
    Clin Auton Res; 2002 Oct; 12(5):393-8. PubMed ID: 12420085
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Failure of the clonidine growth hormone stimulation test to differentiate multiple system atrophy from early or advanced idiopathic Parkinson's disease.
    Clarke CE, Ray PS, Speller JM.
    Lancet; 1999 Apr 17; 353(9161):1329-30. PubMed ID: 10218537
    [No Abstract] [Full Text] [Related]

  • 24. Oral clonidine: an effective provocative test of growth hormone release.
    Salti R, Galluzzi F, Becherucci P, Seminara S, Calzolari C, Innocenti S, La Cauza C.
    Helv Paediatr Acta; 1981 Apr 17; 36(6):527-31. PubMed ID: 7333861
    [Abstract] [Full Text] [Related]

  • 25. Perverted head-shaking and positional downbeat nystagmus in patients with multiple system atrophy.
    Lee JY, Lee WW, Kim JS, Kim HJ, Kim JK, Jeon BS.
    Mov Disord; 2009 Jul 15; 24(9):1290-5. PubMed ID: 19412932
    [Abstract] [Full Text] [Related]

  • 26. Hemodynamic effects of clonidine in two contrasting models of autonomic failure: multiple system atrophy and pure autonomic failure.
    Young TM, Asahina M, Watson L, Mathias CJ.
    Mov Disord; 2006 May 15; 21(5):609-15. PubMed ID: 16404729
    [Abstract] [Full Text] [Related]

  • 27. Increased intracranial volume in Parkinson's disease.
    Krabbe K, Karlsborg M, Hansen A, Werdelin L, Mehlsen J, Larsson HB, Paulson OB.
    J Neurol Sci; 2005 Dec 15; 239(1):45-52. PubMed ID: 16225890
    [Abstract] [Full Text] [Related]

  • 28. The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease.
    Zhang K, Zeng Y, Song C, Fu Y, Wan Q.
    J Neurol; 2010 Sep 15; 257(9):1486-91. PubMed ID: 20405138
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy.
    Schaefer S, Vogt T, Nowak T, Kann PH, German KIMS board.
    J Neuroendocrinol; 2008 Jan 15; 20(1):104-9. PubMed ID: 18081558
    [Abstract] [Full Text] [Related]

  • 32. Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease.
    Pellecchia MT, Pivonello R, Colao A, Barone P.
    Clin Med Res; 2006 Dec 15; 4(4):322-5. PubMed ID: 17210980
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Neuroanatomical correlates of impaired decision-making and facial emotion recognition in early Parkinson's disease.
    Ibarretxe-Bilbao N, Junque C, Tolosa E, Marti MJ, Valldeoriola F, Bargallo N, Zarei M.
    Eur J Neurosci; 2009 Sep 15; 30(6):1162-71. PubMed ID: 19735293
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
    Tompson D, Oliver-Willwong R.
    Clin Neuropharmacol; 2009 Sep 15; 32(3):140-8. PubMed ID: 18978485
    [Abstract] [Full Text] [Related]

  • 36. Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion.
    Tzanela M, Zianni D, Stylianidou Ch, Karavitaki N, Tsagarakis S, Thalassinos NC.
    Clin Endocrinol (Oxf); 2005 May 15; 62(5):597-602. PubMed ID: 15853831
    [Abstract] [Full Text] [Related]

  • 37. Functional aspects of genetic variability in the GH genomic region.
    Gloria-Bottini F, Amante A, Lucarelli P, Saccucci P, Martinoli R, Bottini E.
    J Endocrinol; 2007 Apr 15; 193(1):85-92. PubMed ID: 17400806
    [Abstract] [Full Text] [Related]

  • 38. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy.
    Paviour DC, Thornton JS, Lees AJ, Jäger HR.
    Mov Disord; 2007 Jan 15; 22(1):68-74. PubMed ID: 17089396
    [Abstract] [Full Text] [Related]

  • 39. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
    Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, Takahashi H.
    Brain; 2008 Mar 15; 131(Pt 3):642-50. PubMed ID: 18079166
    [Abstract] [Full Text] [Related]

  • 40. Growth hormone response to low-dose apomorphine in restless legs syndrome.
    Happe S, Bachmann CG, Helmschmied K, Neubert K, Wuttke W, Paulus W, Trenkwalder C.
    Growth Horm IGF Res; 2007 Aug 15; 17(4):323-7. PubMed ID: 17512770
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.